Multi-Gyn ActiGel Plus for Treatment of Bacterial Vaginosis
NCT: NCT04807842 · RECRUITING
Brief Summary
This is a randomized, double-blind, placebo-controlled clinical investigation. The objective of the study is to confirm the efficacy of Multi-Gyn ActiGel Plus to treat BV as compared to a placebo control. Treatment arm 1: Multi-Gyn ActiGel Plus Treatment arm 2: placebo gel Both the Multi-Gyn ActiGel Plus and the placebo will be applied twice a day for 7 consecutive days. Visit 2 will be performed at 3 weeks after start of treatment A phone call will take place, at 5 weeks after start of treatment for subject with clinical cure at Visit 2. The total duration per subject is estimated 5 weeks and the total study duration is 13 months. Sample size is 100 subjects per treatment arm.
Frequently Asked Questions
What is Multi-Gyn ActiGel Plus for Treatment of Bacterial Vaginosis?
Multi-Gyn ActiGel Plus for Treatment of Bacterial Vaginosis is a clinical trial registered under NCT04807842. Current status: RECRUITING.
What is the status of NCT04807842?
The current status of NCT04807842 (Multi-Gyn ActiGel Plus for Treatment of Bacterial Vaginosis) is: RECRUITING.
When did Multi-Gyn ActiGel Plus for Treatment of Bacterial Vaginosis start?
Multi-Gyn ActiGel Plus for Treatment of Bacterial Vaginosis started on 2021-06-11.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.